ASCENDIS PHARMA A/S (ASND)
New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026
New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026
📈 **POSITIVE** • High confidence analysis (85%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical